Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

Ann Oncol. 2010 Jun:21 Suppl 6:vi1-10. doi: 10.1093/annonc/mdq273.

Abstract

The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy for mCRC treatment. The meeting was conducted during the 11th ESMO/World Gastrointestinal Cancer Congress (WGICC) in Barcelona in June 2009. The manuscript describes the outcome of an expert discussion leading to an expert recommendation. The increasing knowledge on clinical and molecular markers and the availability of biological targeted therapies have major implications in the optimal management in mCRC.

Publication types

  • Congress

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Biomarkers / metabolism
  • Carcinoembryonic Antigen / analysis
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / pathology
  • ErbB Receptors / antagonists & inhibitors
  • Humans
  • Microsatellite Instability
  • Mutation
  • Neoplasm Metastasis
  • Prognosis
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins p21(ras)
  • Spain
  • ras Proteins / genetics

Substances

  • Antineoplastic Agents
  • Biomarkers
  • Carcinoembryonic Antigen
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • ErbB Receptors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins